Iannitto, E., Ferrero, S., Bommier, C., Drandi, D., Ferrante, M., Bouabdallah, K., Carras, S., Gini, G., Camus, V., Mancuso, S., Marcheselli, L., Ferrari, A., Merli, M., Tessoulin, B., Stelitano, C., Beldjord, K., Roti, G., Jardin, F., Castagnari, B., Palombi, F., Baseggio, L., Traverse-Glehen, A., Tripodo, C., Liberati, A. M., Parolini, M., Usai, S., Patti, C., Federico, M., Musso, M., Ladetto, M., Zucca, E. and Thieblemont, C. (2024) “Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study”, Haematologica. Pavia, Italy, 109(7), pp. 2297-2302. doi: 10.3324/haematol.2023.284109.